Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 8,375 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of AQX-1125 in Unstable COPD

NCT01954628
View directory record Official record
Conditions
COPD
Interventions
AQX-1125, Placebo
Drug
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Industry
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 23, 2026, 1:33 AM EDT
Completed Phase 3 Interventional

Lactobacillus GG in the Prophylaxis of Ventilator Associated Pneumonia

NCT00613795
View directory record Official record
Conditions
Pneumonia, Ventilator Associated Pneumonia
Interventions
Lactobacillus GG, placebo
Dietary Supplement
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Oct 23, 2026, 1:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential

NCT04274075
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GDC-9545 Tablet, Fasted: Treatment A, GDC-9545 Capsule, Fasted: Treatment B, GDC-9545 Capsule, Fed: Treatment C
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 23, 2026, 1:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair

NCT03206567
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol Supplement capsules, Placebo capsules
Dietary Supplement · Other
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 23, 2026, 1:33 AM EDT
Completed Phase 2Phase 3 Interventional Results available

N-Acetylcysteine for Youth Cannabis Use Disorder

NCT03055377
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
N-acetyl cysteine, Placebo oral capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
14 Years to 21 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 23, 2026, 1:33 AM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

NCT05296512
View directory record Official record
Conditions
Ovarian Clear Cell Carcinoma, Gynecologic Cancer
Interventions
Lenvatinib, Pembrolizumab
Drug
Lead sponsor
Elizabeth K. Lee MD
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 23, 2026, 1:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Absorption, Metabolism and Excretion of Apigenin and Apigenin Glycosides

NCT03526081
View directory record Official record
Conditions
Healthy
Interventions
Chamomile Tea, Parsley based drink, Parsley Yogurt, Apigenin, Parsley-based drink (II)
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 60 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 23, 2026, 1:33 AM EDT
Recruiting Phase 1 Interventional

Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®

NCT06298409
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth
Interventions
CapScan collection capsule
Device
Lead sponsor
Envivo Bio Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 23, 2026, 1:33 AM EDT
Terminated Early Phase 1 Interventional Results available

Vitamin D Supplementation in Women With DCIS and/or LCIS

NCT02936999
View directory record Official record
Conditions
Breast Cancer
Interventions
Cholecalciferol
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 23, 2026, 1:33 AM EDT
Completed Not applicable Interventional Results available

Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD

NCT00363298
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
dextro-amphetamine, Sham Comparison
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 23, 2026, 1:33 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

NCT07559175
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
Interventions
NHS7108, Zenpep®
Drug
Lead sponsor
Aimmune Nestlé Health Science US R&D, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658528
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 23, 2026, 1:33 AM EDT
Completed Phase 1 Interventional

Assess the Oral Bioavailability of New ABT-263 Formulations

NCT00743028
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Lymphomas, Leukemias
Interventions
ABT-263
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
5
States / cities
Encinitas, California • Santa Monica, California • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2010 · Synced Oct 23, 2026, 1:33 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

NCT04477200
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV
Interventions
Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care), Temozolomide
Drug · Radiation · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 23, 2026, 1:33 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease

NCT01731236
View directory record Official record
Conditions
Dietary Modification
Interventions
Carnitine, Choline, Antibiotics, Choline and Aspirin, Carnitine and Aspirin
Dietary Supplement · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 23, 2026, 1:33 AM EDT
Recruiting Not applicable Interventional

Motor Network Physiology

NCT04957095
View directory record Official record
Conditions
Parkinson Disease, Essential Tremor
Interventions
Apomorphine Injectable Solution, Subcortical Stimulation
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

NCT00545532
View directory record Official record
Conditions
Influenza, Human
Interventions
oseltamivir, placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
60
States / cities
Birmingham, Alabama • Beverly Hills, California • Burbank, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 23, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis

NCT01438411
View directory record Official record
Conditions
Bile Acid Synthesis Defect
Interventions
Cholic Acid
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 23, 2026, 1:33 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Allopurinol for Renal Transplant Associated Hypertension in Children

NCT00288171
View directory record Official record
Conditions
Hypertension, Renal Transplant
Interventions
Placebo, Allopurinol
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 23, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Use of Oracea and Epiduo Forte in Severe Acne Patients

NCT03457636
View directory record Official record
Conditions
Acne
Interventions
Doxycycline Anhydrous 40 MG, Adapalene/Benzoyl Peroxide Gel 0.3-2.5%
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 23, 2026, 1:33 AM EDT
Withdrawn Not applicable Interventional

Vitamin C & Exercise Induced Bronchoconstriction (EIB)

NCT03610932
View directory record Official record
Conditions
Exercise-induced Bronchospasm
Interventions
Vitamin C, Placebo
Dietary Supplement · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 23, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

NCT01945775
View directory record Official record
Conditions
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions
talazoparib, Physician's-Choice
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
207
States / cities
Flagstaff, Arizona • Scottsdale, Arizona • Antioch, California + 136 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 23, 2026, 1:33 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects

NCT01818011
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 Initial fit for purpose tablets, GSK1322322 over granulated tablets, GSK1322322 intended commercial tablets, Placebo tablets, 13C-GSK1322322 stable isotope powder, GSK1322322 for injection, Placebo injection
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 23, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

NCT01384734
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg, Tenofovir 300 mg, Ritonavir 100 mg, Atazanavir 300 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
13
States / cities
San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 23, 2026, 1:33 AM EDT